DBS: Initiates coverage on Akeso Biopharma (02675) with a "buy" rating and a target price of HKD 68.1.

Standard Chartered released a research report stating that it initiated coverage on Jingfeng Medical (02675) for the first time, giving it a "buy" rating with a target price of HK$68.1. The forecasted compound annual growth rate of net profit from 2026 to 2028 is 187%, and the forecasted compound annual growth rate of revenue from 2026 to 2030 is 49%, reaching 4.3 billion RMB. The bank expects that with the key advantages of its core product MP1000, Jingfeng Medical is expected to achieve breakeven in 2026. The bank believes that the overseas market is the main growth driver for Jingfeng Medical, as it has obtained registration approvals in 55 countries and regions. However, global tensions may slow down the company's market penetration.